Cargando…

Ospemifene for vulvar and vaginal atrophy: an overview

The menopause-related decline in estrogen levels leads to an array of genital, sexual, and urinary symptoms collectively known as genitourinary syndrome of menopause. The constellation of symptoms associated with vulvar and vaginal atrophy (VVA) can have a profoundly detrimental effect on a woman’s...

Descripción completa

Detalles Bibliográficos
Autor principal:	Palacios, Santiago
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337588/ https://www.ncbi.nlm.nih.gov/pubmed/32670378 http://dx.doi.org/10.7573/dic.2020-3-2

Ejemplares similares

Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy
por: Palacios, Santiago, et al.
Publicado: (2016)

Experience with ospemifene in patients with vulvar and vaginal atrophy and urinary incontinence: case studies
por: Blanco, Zuramis Estrada, et al.
Publicado: (2020)

Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles
por: del Carmen Pingarrón Santofimia, María, et al.
Publicado: (2020)

The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy
por: Nappi, R. E., et al.
Publicado: (2015)

Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy
por: Bruyniks, N., et al.
Publicado: (2016)

Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies
por: Lilue, Mariella, et al.
Publicado: (2020)

Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy
por: Goldstein, S. R., et al.
Publicado: (2014)

Experience with ospemifene in patients with vulvar and vaginal atrophy and associated sexual dysfunction: case studies
por: López, Ana Rosa Jurado, et al.
Publicado: (2020)

Ospemifene in the Management of Vulvar and Vaginal Atrophy: Focus on the Assessment of Patient Acceptability and Ease of Use
por: Cagnacci, Angelo, et al.
Publicado: (2020)

Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast
por: Soe, Lin H, et al.
Publicado: (2013)

Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
por: Wurz, Gregory T, et al.
Publicado: (2014)

Ospemifene May Not Treat Vulvar Atrophy: A Report of Two Cases
por: Goldstein, Andrew T., et al.
Publicado: (2016)

Effect of Ospemifene on Densitometric and Plasma Bone Metabolism Biomarkers in Postmenopausal Women Reporting Vulvar and Vaginal Atrophy (VVA)
por: Maffei, Silvia, et al.
Publicado: (2022)

Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices
por: Goldstein, Irwin, et al.
Publicado: (2019)

Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial
por: Constantine, G., et al.
Publicado: (2015)

Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy
por: Shin, Jae Jun, et al.
Publicado: (2017)

Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey
por: Nappi, R. E., et al.
Publicado: (2016)

Vaginal dehydroepiandrosterone compared to other methods of treating vaginal and vulvar atrophy associated with menopause
por: Pięta, Wojciech, et al.
Publicado: (2021)

Experience with ospemifene in patients with vulvovaginal atrophy treated with laser therapy: case studies
por: Salcedo, Félix Lugo, et al.
Publicado: (2020)

Experience with ospemifene in a patient with vulvovaginal atrophy and dyslipidemia: a case study
por: Rodríguez, Silvia Pilar González
Publicado: (2020)

Multidisciplinary Overview of Vaginal Atrophy and Associated Genitourinary Symptoms in Postmenopausal Women
por: Goldstein, Irwin, et al.
Publicado: (2013)

Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis
por: Simon, James A., et al.
Publicado: (2023)

Human papillomavirus in vulvar and vaginal carcinoma cell lines
Publicado: (1995)

Human papillomavirus in vulvar and vaginal carcinoma cell lines.
por: Hietanen, S., et al.
Publicado: (1995)

Vulvar and Vaginal Melanomas—The Darker Shades of Gynecological Cancers
por: Dobrică, Elena-Codruța, et al.
Publicado: (2021)

Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial
por: Archer, David F., et al.
Publicado: (2019)

Recognition and diagnosis of vulvar dermatoses
por: Mauskar, Melissa M.
Publicado: (2021)

Vulvar biopsy reimbursement rates
por: Kraus, Christina N., et al.
Publicado: (2022)

WISDOM survey: attitudes and behaviors of physicians toward vulvar and vaginal atrophy (VVA) treatment in women including those with breast cancer history
por: Kingsberg, Sheryl A., et al.
Publicado: (2019)

The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy
por: Constantine, Ginger D., et al.
Publicado: (2017)

Endometrial safety of ospemifene: results of the phase 2/3 clinical development program
por: Constantine, Ginger D., et al.
Publicado: (2015)

Other Gynecologic Cancers: endometrial, ovarian, vulvar and vaginal cancers
por: Duarte-Franco, Eliane, et al.
Publicado: (2004)

Incidence and cost of anal, penile, vaginal and vulvar cancer in Denmark
por: Olsen, Jens, et al.
Publicado: (2012)

Vaginal microbiota signatures in healthy and purulent vulvar discharge sows
por: Poor, André P., et al.
Publicado: (2022)

Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study
por: Nordstrom, Beth L., et al.
Publicado: (2022)

Gynecologic tumor board: a radiologist’s guide to vulvar and vaginal malignancies
por: Chow, Lucy, et al.
Publicado: (2021)

Vulvar Cancer: Facing a Rare Disease
por: Preti, Mario, et al.
Publicado: (2022)

Effects of Ospemifene on Drug Metabolism Mediated by Cytochrome P450 Enzymes in Humans in Vitro and in Vivo
por: Turpeinen, Miia, et al.
Publicado: (2013)

Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence
por: Archer, David F., et al.
Publicado: (2015)

Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials
por: Simon, James A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_pv9ci5lc4bkuknu4b3a4cbq9qu